The hepatitis B virus DNA is 10^4, which is a moderate viral load and is relatively weakly infectious. The need for treatment should be systematically analyzed in conjunction with the body’s liver function, morphological structure of the liver, blood count, and methemoglobin. If liver function is persistently abnormal and has been for 3-6 months, antiviral therapy can be administered. Among the options for antiviral therapy are interferon antiviral therapy and nucleoside antiviral therapy. Interferon antiviral therapy is indicated for patients with low viral load, low surface antigen and young age, while nucleoside antiviral therapy is indicated for patients who are not suitable for interferon antiviral therapy. If you are eligible for antiviral therapy, you need to actively pursue antiviral therapy. If you are not eligible for antiviral therapy, you need to regularly review hepatitis B DNA, liver function, abdominal ultrasound, alpha-fetoprotein, and blood count.